A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.

Phase 2

GERCOR - Multidisciplinary Oncology Cooperative Group
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Ipsen
Pfizer

Angiopeptin
Lanreotide
Somatostatin
Sunitinib